Table 2.
Epidemiologic studies investigating associations between circulating oxylipins in pregnancy and preterm birth (PTB)
| Referencea | Country | Study design and sample size | Timingb | Matrix | Oxylipins measured | PTB associationsc |
|---|---|---|---|---|---|---|
| Aung et al. (2019) | USA | Design: Prospective case-control Sample: N=173; n=58 PTB (spontaneous, placental) |
Trimester 2 | Plasma, urine | 48 oxylipins in plasma (all major enzymatic pathways) AA-nonenzymatic: 8-isoprostane (urine, total) | (+) LA-CYP/LOX (+/−) AA-CYP (+) AA-LOX/COX (+) 8-isoprostane |
| Borkowski et al. (2020) | USA | Design: Prospective matched case-control Sample: N=102; n=51 PTB (<31 weeks) |
Trimester 2 | Serum | 82 oxylipins (all major enzymatic pathways; AA- nonenzymatic pathway) | (+) AA-CYP/LOX/COX oxylipins (+) LA-CYP/LOX oxylipins (+) F2-isoprostanes |
| Eick et al. (2020) | Puerto Rico |
Design: Prospective Sample: N=469, n=50 PTB |
Trimesters 2-3 (3 samplings) | Urine | AA-COX: PGF2α AA-nonenzymatic: 8-isoprostane (free), 8-isoprostane metabolite |
(+) 8-isoprostane (+) 8-isoprostane metabolite (+) PGF2α |
| Rosen et al. (2019) | USA | Design: Prospective Sample: N=740; n=61 PTB (overall, spontaneous) |
Trimester 3 | Urine | AA-COX: PGF2α AA-nonenzymatic: 8-isoprostane (free), 8-isoprostane metabolite |
(+) 8-isoprostane metabolite |
| (Svenvik et al., 2021) | Sweden | Design: Cross-sectional (PTB-only) Sample: N=80; n=21 PTB (<34 weeks) |
Delivery or Trimester 3 | Plasma | 67 oxylipins (all major enzymatic pathways) | (−) 9,10-DiHOME (LA-LOX) and 9,10-DiHODEs (αLA-LOX) (+) 8-HETE (AA-LOX) |
| Ferguson et al. (2015) | USA | Design: Prospective case-control Sample: N=482; n=130 PTB (spontaneous, placental) |
Trimesters 1-3 (4 samplings) | Urine | AA-nonenzymatic: 8-isoprostane (total) | (+) 8-isoprostane |
| Hsieh et al. (2012) | Taiwan | Design: Prospective Sample: N=503; n=17 PTB |
Trimester 2 | Plasma | AA-nonenzymatic: 8-isoprostane | |
| Ilhan et al. (2015) | Turkey | Design: Cross-sectional matched case-control Sample: N=72*, n=34 PTB * |
Delivery | Plasma | AA-nonenzymatic: 8-isoprostane | (−) 8-isoprostane |
| Mestan et al. (2012) | USA | Design: Cross-sectional Sample: N=237 PTB (≤28, 29-33, and <37 weeks) |
Delivery | Cord blood plasma | AA-nonenzymatic: 8-isoprostane | (+) 8-isoprostane (early vs late PTB) |
Abbreviations: 8-isoprostane, 8-iso-prostaglandin-F2α; AA, arachidonic acid; COX, cyclooxygenase; CYP, cytochrome P450; LA, linoleic acid; LOX, lipoxygenase; PG, prostaglandin
Reference studies were identified in PubMed using a multi-stage approach. First, the following search phrase was used to identify an initial list of human studies published since 2010: (preterm OR gestational age) AND (oxylipin OR eicosanoid OR bioactive lipid OR isoprostane) AND (inflammation OR oxidative stress) AND (2010/1/1:2022/02/01[pdat]) AND (humans[Filter]) AND (english[Filter]) NOT (review[Filter] OR systematicreview[Filter]). This search produced 145 results, which were then paired down to the 9 reviewed studies of preterm birth after excluding duplicates and reviewing articles for relevant areas of focus.
Single spot sample collected unless otherwise noted
Null associations left blank